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Clinical and morphologic features of human immunodeficiency virus (HIV)-associated nephropathy (HIVAN), such as proteinuria,
sclerosing glomerulopathy, tubular degeneration, and interstitial disease, have been modeled in mice bearing an HIV proviral transgene
rendered noninfectious through a deletion in gag/pol. Exploring the genetic basis of HIVAN, HIV transgenic mice bearing mutations in either
or both of the accessory genes nef and vpr were created. Proteinuria and focal glomerulosclerosis (FGS) only developed in mice with an intact
vpr gene. Transgenic mice bearing a simplified proviral DNA (encoding only Tat and Vpr) developed renal disease characterized by FGS in
which Vpr protein was localized to glomerular and tubular epithelia by immunohistochemistry. The dual transgenic progeny of HIV[Tat/Vpr]
mice bred to HIV[DVpr] proviral transgenic mice displayed a more severe nephropathy with no apparent increase in Vpr expression,
implying that multiple viral genes contribute to HIVAN. However, the unique contribution of macrophage-specific Vpr expression in the
development of glomerular disease was underscored by the induction of FGS in multiple murine lines bearing a c-fms/vpr transgene.
Crown Copyright D 2004 Published by Elsevier Inc. All rights reserved.Keywords: AIDS; Retrovirus; Nef; Kidney; MacrophageIntroduction
Vpr protein is an accessory gene product of human
immunodeficiency virus type 1 (HIV-1) exhibiting pleiotro-
pic roles in the replicative cycle of the virus and on host
gene expression. Vpr is packaged in the virion particle (Lu
et al., 1993) and has an early role in the infection of
nondividing cells by facilitating the nuclear transport of
the virion core (Heinzinger et al., 1994; Hrimech et al.,
1999). Vpr is synthesized late in the replication cycle and
can induce terminal differentiation in producing cells (Levy
et al., 1993), cell death (Planelles et al., 1995; Stewart et al.,
1997), alterations in host cell activation (Kino et al., 1999;
Kulkosky et al., 1999), and viral transcription (Bukrinsky
and Adzhubei, 1999; Gummuluru and Emerman, 1999). A0042-6822/$ - see front matter. Crown Copyright D 2004 Published by Elsevier
doi:10.1016/j.virol.2004.01.026
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Edmonton, Alberta, Canada T6G 2S2. Fax: +1-780-492-9828.
E-mail address: peter.dickie@ualberta.ca (P. Dickie).late function may be to boost virus production and trans-
mission through the induction of G2 arrest (Jowett et al.,
1995; Trono, 1995; Yao et al., 1998). The latter effect may
be mediated by interactions with the transcriptional factor
TFIIB (Agostini et al., 1999) or changes in the cytoskeletal
structure of the host cell (Gu et al., 1997; Matarrese et al.,
2000). Despite diverse cellular effects, there has been
surprisingly little evidence of Vpr-related cytotoxicity in
vivo. Dispensible in vitro for virus replication and cytopa-
thicity in T cells (Trono, 1995), it is also dispensible for T
cell loss in a model of HIV infection (Aldrovandi and Zack,
1996) and AIDS in a model of SIV infection (Baba et al.,
1999; Gibbs et al., 1995). Alternatively, Vpr may have a
unique function in cells of the macrophage lineage where a
positive effect on virus replication has been demonstrated
(Balliet et al., 1994; Connor et al., 1995; Sherman et al.,
2003).
Models of chronic HIV-1 infection exist in mice trans-
genic for proviral sequences. These have been useful for
studying proviral gene activation in macrophages (Dickie et
al., 2001; Gazzinelli et al., 1996; Schito et al., 2001).Inc. All rights reserved.
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important factor contributing to the persistent infection of
humans (Crowe, 1995). We have assessed the toxicity of
Vpr in transgenic animals carrying noninfectious HIV
proviral DNA (gag and pol sequences were deleted). The
vpr gene was genetically manipulated and its toxicity
evaluated in the context of a nephropathy previously de-
scribed in HIVDGag/Pol mice (Dickie et al., 1991). These
mice model a disease remarkably similar to HIV-associated
nephropathy (HIVAN) in humans (Barisoni et al., 2000;
Bruggeman et al., 1997; Dickie et al., 1991). Exploring a
role for macrophages (or macrophage-like cells) in the
etiology of HIVAN, Vpr expression was also linked to the
macrophage-specific murine exon 2 c-fms promoter in novel
transgenic mouse lines.
Renal disease has been associated with other immuno-
deficiency viruses such as the feline- (Poli et al., 1993) and
simian-associated (Alpers et al., 1997) viruses. In humans,
nephropathy of diverse forms has been described, including
sclerosing and immune-complex mediated forms of glomer-
ulopathy and tubulointerstitial diseases. On the basis of the
appearance of unique clinical features, HIV-associated ne-
phropathy was recognized as the most prevalent form of
kidney disease in HIV-infected populations (D’Agati and
Appel, 1998). It affects a significant proportion of seropos-
itive individuals (up to 10% of infected individuals, depend-
ing on the study), most notably amongst African-Americans
and cases of pediatric AIDS. The principle histopathological
lesion in humans is collapsing focal glomerulosclerosis
(FGS) associated with podocyte hypertrophy, diffuse
mesangial hyperplasia, and extracellular matrix deposition
(D’Agati and Appel, 1998). Tubulointerstitial disease is also
prevalent, marked by tubular epithelial cell simplification,
tubular atrophy, microcystic dilatation, and inflammation.
Despite the episodic detection of viral DNA and antigen in
renal biopsies (Cohen et al., 1989; Green et al., 1992;
Kimmel et al., 1993), and the in vitro infection of various
renal cell types (Green et al., 1992; Ray et al., 1997), it
remains unclear what renal cell types are permissive for
HIV-1 replication in vivo. Coreceptor expression on both
mesangial and tubular epithelial cell types has been pro-
posed (Conaldi et al., 1998; Eitner et al., 1998) and tissue
macrophages are likely to reside in the glomerular space
(Sasmono et al., 2003). Cytopathic viral proteins may act
directly on one or more of these glomerulus-associated cells
(Bodi et al., 1995; Conaldi, 1998), or they may act by
disrupting the cytokine milieu of the kidney (Rappaport et
al., 1994).
HIVAN in transgenic mice (Dickie et al., 1991) featured
glomerular and tubular defects in common with human
HIVAN. Transplantation experiments implicated renal pro-
duction of HIV gene products (Bruggeman et al., 1997) in
the disease. Inactivation of nef did not prevent glomerular
disease in one proviral transgenic line studied (Kajiyama et
al., 2000). Genetic complementation with Nef, however, did
substantiate its contribution in renal interstitial inflammation(Kajiyama et al., 2000), an observation independently made
in transgenic mice expressing Nef under the transcriptional
control of the human CD4 promoter (Hanna et al., 1998).
We reported herein, on a similar approach, to evaluate the
toxicity of HIV-1 Vpr on renal epithelia.Results
Derivation and characterization of HIV proviral transgenic
lines
The prototype HIV-1 transgenic mouse line (line T26)
that developed HIVAN bore a DGag/Pol HIV-1 proviral
DNA (pEVd1443 sequences originally derived from clone
pNL4-3) (Dickie et al., 1991). Inactivation of the nef gene
in an independent HIVd1443 transgenic line (X5 mice)
mitigated but did not prevent the development of murine
HIVAN (Dickie, 2000; Kajiyama et al., 2000). A patho-
logic role for HIV-1 Vpr was explored through the
creation of novel HIV transgenic lines in which the vpr
gene of pEVd1443 and its DNef counterpart pX5 was
mutated by frameshifting at the unique EcoRI restriction
site (base position 5743; Fig. 1). Two new HIV-1 trans-
genic lines were produced: V13 (DVpr) and VN15
(DVprDNef). For the purpose of complementing these
lines with vpr, pEVd1443 was modified by sequential
deletion of vif, vpu, env, nef, and rev, leaving only the
genes for Tat and Vpr intact (HIV[Tat/Vpr] transgene;
Fig. 1). A second vpr orf was inserted in the 3V position
once occupied by nef to enhance the likelihood of Vpr
expression.
Line V13 was one of six HIVd1443[DVpr] lines
screened for viral gene expression by Northern analysis.
V13 mice produced HIV transcripts in the skin, eye, and
muscle with much reduced levels appearing in the kidney
and lymphoid tissues (Fig. 2). V13 transgenic mice dis-
played perinatal, nuclear cataracts (absent the microphthal-
mia characteristic of T26 wild-type mice; Dickie, 1996) and,
unique to our hemizygous HIV lines, were runted relative to
nontransgenic littermates. Viral gene expression was not
detected in tissues of the remaining five HIVd1443[DVpr]
lines, and all were phenotypically normal. Line VN15 was
one of eight HIVd1443[DVprDNef] lines analyzed. Viral
gene transcription was observed in four of the derived lines,
predominantly in the skin. The highest level of expression
was observed in line VN15. VN15 animals also expressed
HIV RNA in the eye (Fig. 2). Hemizygous VN15 mice were
visibly normal but homozygous offspring of this line (>30
observed) developed hyperkeratosis and necrotic lesions on
the tail as did homozygous T26 mice (Santoro et al., 1994)
and infectious proviral HIV-1 transgenic mice (Leonard et
al., 1988).
Seven HIV[Tat/Vpr] mouse lines were analyzed. HIV
transcripts were detected by Northern analysis in only one
(line TV2). TV2 transgenic mice expressed viral RNA in the
Fig. 1. HIV transgenes. The subgenomic HIV proviral transgene
HIV[DGag/Pol], derived from pEVd1443, was mutated in vpr and nef by
frameshifting at EcoRI or XhoI sites, respectively. After linearization by
codigestion with FspI and NaeI, mutated constructs were microinjected to
create X5 (DNef), V13 (DVpr), and VN15 (DVprDNef) transgenic mice.
The HIV[Tat/Vpr] transgene was excised from pTV2 DNA that was
constructed through sequential deletion of pEVd1443. The two exons of tat
remain intact (stippled boxes) and an additional vpr gene (hatched box) was
inserted adjacent to the 3V long terminal repeat (LTR). The c-fms/vpr
transgene was derived from p7.2fms-EGFP by replacing the EGFP gene
with a viral RsaI vpr fragment (hatched box) between the c-fms promoter
and SV40 termination signals (gray box).
Fig. 2. Proviral gene expression. Tissue expression profiles for HIV proviral
transgenic mouse lines were produced by Northern blot analysis. Total
RNA was fractionated in 1.25% denaturing agarose and blotted onto
nitrocellulose membranes. HIV RNA was detected using a radiolabeled
probe complementary to the 3V end of viral transcripts. Blotting for h-actin
RNA controlled for sample loading. Animals were hemizygous for their
respective transgenes, female, and between 24 and 35 days old. L. Nodes:
lymph nodes.
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normally to adulthood and were visibly indistinguishable
from nontransgenic littermates. However, nursing TV2
mothers (2–3 months of age) became moribund (13/13
mice, mean of 12 days post-partum) with signs of severe
subcutaneous edema typical of wild-type HIVd1443 trans-
genic (T26) mice with renal failure. Homozygous offspring
of TV2 crosses (male or female) became moribund around 3
months of age also with signs of subcutaneous edema (8/8;
mean age of 105 days). In contrast, the incidence of
morbidity in hemizygous TV2 mice (males and virgin
females) was around 5% (3/59) for animals under 6 months
of age.
HIV gene expression in HIV[Tat/Vpr] kidneys
Failing to detect Vpr protein in TV2 renal tissue by
Western analysis, RT-PCR was performed on kidney RNA
using the primer pair 045/RV1 (see Materials and methods)
to detect spliced transcripts for Tat (338 and 411 bp), Vpr
(725 bp), and full-length transcripts (at 1272 bp). The sizes
of amplified cDNA sequences were predicted from splic-ing reactions for the parental NL4-3 virus (Purcell and
Martin, 1993). Viral transcripts were detected in kidneys of
1- and 3-month-old hemizygous TV2 mice (Fig. 3). An
Fig. 3. Viral gene expression in HIV[Tat/Vpr] (TV2) kidneys. To detect vpr
and tat transcripts, RT-PCR using a primer pair that spanned major 5V splice
junctions in HIV-1 (045/RV1) was used. Panel A: HIV transgene expression
was detected in renal tissue of a TV2 hemizygous female (lane 2) and a 3-
month-old nursing female sibling (lane 3), a young TV2 hemizygous
female (5-week-old, lane 5), and a homozygous TV2 female sibling (lane
6). RT-minus samples (left lane of each set) were amplified to control for
DNA contamination. Amplified products were separated in 2% agarose,
stained with ethidium bromide, and identified based on predicted sizes for
HIV mRNA spliced transcripts. Four HIV-specific amplification products
were detected with sizes near 1272, 725, 411, and 338 bp, corresponding to
full-length Vpr and two Tat transcripts (the larger of which is identified by
the labeled arrow), respectively. Nontransgenic kidneys (lanes 1 and 4)
lacked virus-specific bands but were positive for a nonspecific product near
500 bp. Panel B: Levels of transcription were computed from digital images
of agarose gels in which three sibling pairs of homozygous/hemizygous
female TV2 mice, as well as four sibling pairs of nursing/virgin TV2
females, were assayed in triplicate. Values were normalized to the amount
of GAPDH cDNA as determined by RT-PCR. Full-length (fl) transcript: o;
vpr: 4; tat: 5. TV2* mice were hemizygous and 3 months old; TV2 mice
were 5-week-old hemizygous (/+), or homozygous (+/+). Error bars
represent one standard deviation.
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homozygous TV2 progeny relative to hemizygous sibling
mice. This increase was apparent for putative vpr tran-
scripts and the putative tat transcripts but not full-length
HIV transcripts. Full-length transcripts were increased in
nursing females relative to age-matched, virgin sibling
mice, concurrent with modest increases in transcripts
related to vpr and tat genes based on predicted product
sizes. Neither gene dosage nor the physiologic conditions
peculiar to nursing mice appeared to alter the ratio of the
two small transcripts.
Ultrastructural changes and Vpr deposition in TV2 renal
tissue
Characteristic features of HIV-associated nephropathy
were observed by electron microscopy in sections of 6-
month-old TV2 kidneys: podocytes displayed foot process
effacement, capillary lumen were collapsed, basement mem-
branes were focally thickened and wrinkled, and there was
microvillous transformation (Figs. 4A, B). Previously, HIV-
related protein was detected immunologically in glomeruli
and tubular epithelia of T26 and X5 transgenic mice (Dickie
et al., 1991; Kajiyama et al., 2000). Similarly, TV2 kidney
sections were screened with a polyclonal antibody raised
against a peptide fragment of Vpr (residues 1–46). Though
Vpr was not detectable in kidneys of virgin hemizygous
TV2 animals, it was detected in kidneys of lactating
hemizygous TV2 females (Figs. 4C, D). Vpr was localized
to the renal cortex, near apical regions or brush borders of
the occasional proximal tubular epithelial cell. Staining of
the occasional glomeruli for Vpr protein followed a seg-
mental pattern. This tissue localization was consistent with
endogenous expression in glomerular epithelia, the trapping
of Vpr within sclerotic glomeruli, or its reabsorption by
tubular epithelial cells.
Vpr gene expression in kidneys of HIVd1443 mice
By RT-PCR, levels of vpr expression were compared in
wild-type HIVd1443 (T26) mice, DNef and DVpr counter-
parts (X5, V13, and VN15), and TV2 mice (Fig. 5). Mutant
transcripts of vpr were distinguished from wild-type tran-
scripts based on the susceptibility of amplified cDNA
products to EcoRI cleavage. Vpr sequences (633 bp product
amplified with primer pair L2/VH2) were prominent in T26
mice, less so in X5 mice and TV2 mice. Wild-type vpr
transcript was not observed in either V13 or VN15 mice
(Fig. 5B). When these latter lines were crossed with TV2
mice, the observed level of native vpr transcript was similar
to that observed in TV2 mice alone (Fig. 5B). Likewise, no
significant change was observed in the expression of the 3V
vpr gene of TV2 (screened using primer pair LV1/R3, Fig.
5C) in TV2-complemented HIVd1443 mice.
The apparent decrease in vpr expression in X5 (DNef)
mice relative to wild-type T26 mice, when total HIV gene
Fig. 4. Ultrastructural changes and localization of Vpr. Glomerular epithelia of a wild-type mouse (A) is compared to that of a hemizygous TV2 mouse (B) by
transmission electron microscopy (original magnification 7400). Glomerular epithelial cells (EC) and their characteristic foot processes (arrow heads, upper
left, panel A) are evident adjacent to patent capillaries in the normal animal. CL: capillary lumen. In the TV2 animal (panel B), capillary lumen are collapsed
(CL, upper left), foot processes are effaced, the basement membrane is wrinkled and thickened (white arrow heads), and there is microvillous transformation
(star, left of panel). EN: endothelial cell. Scale bar is equivalent to 2 AM. In panels C and D, renal tissue from a lactating TV2 female was immunostained with
control rabbit serum (C) or anti-Vpr antiserum (D). Vpr protein was detected in proximal tubular epithelial cells (brush borders or apical cytoplasmic domains)
and glomeruli (right side of panel). Original magnification was 80 (scale bar equivalent to 60 AM).
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splicing was different in X5 mice. Splicing differences
were probed by screening for Rev-encoded products at
136, 142, and 160 bp; Env at 120 and 136 bp; Tat at 319
bp; and Nef at 120 bp, the sizes of which were predicted
from known viral splicing products (Purcell and Martin,
1993). HIVd1443 (T26) kidney RNA yielded predominant
fragments of 120 bp (corresponding to putative Env or Nef
transcripts) and 633 bp (for Vpr) (Fig. 5D). By compari-
son, X5(DNef) RNA yielded less vpr-specific transcript,
consistent with experiments shown in Fig. 5C. The inac-
tivation of vpr (in V13 mice) was associated with reduced
levels of 120–140 base pair products, consistent with
either nef or env transcripts (Fig. 5D). The most striking
difference in VN15 (DNefDVpr) mice was an enhanced
level of RT-PCR product near 320 base pairs (the putative
tat product) that was absent in animals inheriting the TV2
transgene.Characterization of c-fms/vpr transgenic mice
Given the propensity of HIV-1 provirus transgenic mice
to express viral genes in macrophages and the presence of
macrophages in renal glomeruli and tubules (Sasmono et al.,
2003), we assessed the renal toxicity of Vpr in mice
transgenic for a c-fms/vpr gene. The exon-2 c-fms promoter
is specific for macrophages (Himes et al., 2001). The M-
CSF receptor may also be expressed in mesangial cells of
renal glomeruli, a cell type with macrophage-like character-
istics (Watanabe et al., 2001). Founder mice and heterozy-
gous offspring bearing the c-fms/vpr transgene (Fig. 1) were
visibly normal. In two of three lines analyzed (MeRV4 and
MeRV21), transgenic mothers displayed a transient edema
between 12 and 15 days of lactation. Unlike TV2 mothers,
however, MeRV females survived to produce multiple
litters. Females in the third MeRV line (MeRV8) nursed
without complication.
Fig. 5. Kidney-associated viral gene expression in HIVd1443 transgenic lines. Levels of HIV transcript in kidneys were detected by RT-PCR using the primer
pairs shown in A. The primer pair L2/VH2 detected cDNAs encoding vpr in the native position (shaded box; nef is shown as the hatched box) of both
HIVd1443 and TV2 transgenes. The LV1/R3 primer pair was used to detect cDNA products specific for the 3V vpr of the TV2 transgene. The L2/VH2 primer
pair amplified a 633 bp DNA product corresponding to vpr-containing cDNAs, visualized by ethidium bromide staining (B). Mutant vpr was verified by the
insensitivity of cDNAs to EcoRI cleavage (in V13 and VN15 samples). Measurement of GAPDH-related product controlled for cDNA synthesis. Mice were
approximately 4 weeks old. Shown is one of duplicate experiments. M: DNA ladder; RT: reverse transcriptase. Similarly, the LV1/R3 primer pair was used to
amplify a 381 bp product of cDNAs bearing the 3V vpr gene in TV2, as a measure of 3V vpr expression in the kidney (C). Shown is one of triplicate assays. In
panel D, RT-PCR was repeated using the L2/VH2 primer pair, labeling PCR products with 32P-dCTP. Products were fractionated in 5% acrylamide and exposed
to X-ray film. Native vpr transcripts produced an amplified DNA of 633 bp (B). Differentially spliced transcripts produced a variety of smaller amplified DNA
products in animals of different transgenotypes. Shown is one of duplicate experiments using different groups of animals from those tested in B. Lanes
identified by two transgenes denote dual transgenic animals.
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RT-PCR using a primer pair nested in the vpr gene (LV1/
RV1). Heterozygous female mice from the three MeRV lines
were compared to TV2 mice (Fig. 6). Each of the three
MeRV lines expressed the vpr gene in the kidney, the
highest levels appearing in MeRV21 animals. The level of
vpr expression in each was consistently less than that
observed in TV2 mice.
Renal dysfunction in association with the vpr gene
Renal disease in HIVd1443 wild-type transgenic mice is
marked by a transient proteinuria between 3 and 5 weeks of
age (Dickie et al., 1991). In X5 (HIVd1443[DNef]) mice,
proteinuria is less severe (Kajiyama et al., 2000; Table 1).
Proteinuria was not observed in HIVd1443 DVpr lines
(screening twice weekly between 3 and 10 weeks of age).Urine protein levels in V13 mice were actually subnormal,
perhaps reflecting the poor growth characteristics of these
mice. Amongst the HIV[Tat/Vpr] lines, only the TV2 line
displayed elevated protein excretion. Hemizygous TV2
mice at 5–8 weeks of age displayed modestly elevated
levels of urine protein (Fig. 7A), but changes did not match
the significance of T26 or X5 animals (Table 1). By
comparison, high urine protein levels distinguished homo-
zygous TV2 mice (3 control values). Lactating female
TV2 mice at 10 days post-partum displayed urine protein
levels well above normal (1220 F 230 vs. 260 F 140 mg/dl
for nontransgenic nursing mice; n = 7). Thus, increased
levels of proteinuria mirrored the increased morbidity in
TV2 mice.
The development of proteinuria and morbidity in TV2
hemi- and homozygous mice, coupled with the absence of
renal disease in the Tat-positive, Vpr-deficient HIVd1443
Fig. 6. Vpr expression in c-fms/vpr (MeRV) mice. By RT-PCR, renal vpr
expression in MeRV transgenic mice was compared to vpr expression in
HIV[Tat/Vpr] mice (HIV/TV2). The primer pair LV1/RV1 was used (Table
2). GAPDH expression controlled for cDNA synthesis, and values used for
normalization. Amplification products were separated in agarose, stained
with ethidium bromide, and quantitated by densitometry. Mean results from
three mice each (2-month-old females) are shown in the histogram. RT+:
plus reverse transcriptase; RT: less reverse transcriptase.
Fig. 7. Proteinuria in HIV proviral transgenic mice. Urine protein levels (A)
in hemizygous TV2 mice (n = 12) are compared to nontransgenic siblings
(FVB/N, n = 12) and mice homozygous for the transgene (TV2/TV2, n =
4). In B, the hemizygous offspring of V13  TV2 breeding pairs were
analyzed for urine protein (TV2, n = 2; V13, n = 3; V13/TV2 dual
transgenic offspring, n = 3). Eight hemizygous T26 mice (.) and five
VN15/TV2 mice (4) are included for comparison. Average urine protein
values for transgenic mice are presented, after normalization to urine
protein levels in nontransgenic siblings (for example, T26 mice had urine
protein levels 4-fold greater than nontransgenic siblings at 21 days of age).
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HIVAN. Exploring a role for secondary viral factors, and in
particular Nef, Vpr-deficient V13 and VN15 mice were
complemented with vpr through breeding with TV2 mice.Table 1
Hemizygous HIV transgenic lines and their susceptibility to HIV-associated
nephropathy (HIVAN)
Transgenotype
(encoded genes)
Lines
expressing
HIV
Established
line
Urine
protein (mg/dl)
HIVd1443
(vpu, vpr, vif, tat, nef, env)
4/8 T26 2155 F 250
HIVd1443[DNef]
(vpu, vpr, vif, tat, env)
1/7 X5 1370 F 514
HIVd1443[DVpr]
(vpu, vif, tat, nef, env)
1/6 V13 150 F 40
HIVd1443[DVprDNef]
(vpu, vif, tat, env)
4/8 VN15 265 F 65
HIV[Tat/Vpr] (tat, vpr) 1/7 TV2 390 F 120
HIV genes present in each line are shown in italics. The fraction of founder
lines that expressed viral genes as detected by Northern analysis is shown.
Urine protein levels are presented for HIV transgenic females at 35 days of
age (n = 12). Control FVB/N mice had a urine protein level of 310 F 100
mg/dl at this age. Variability is given as one standard deviation. The
elevation in TV2 urine protein (relative to nontransgenic controls) was not
significant (to P < 0.01).
Error bars have been omitted for clarity (see Table 1 for typical error
values). TV2 (E); V13 (n); TV2/V13 (o).VN15/TV2 dual transgenic mice were indistinguishable
from sibling mice bearing only the TV2 transgene in that
they developed a mild proteinuria (Fig. 7B) with no asso-
ciated morbidity. In contrast, urine protein levels in V13/
TV2 mice were elevated almost threefold relative to non-
transgenic sibling mice (Fig. 7B) and 6 times that of their
runted V13 transgenic siblings. V13/TV2 mice died at the
mean age of 40 days (5/5 mice).
C-fms/vpr (MeRV) mice displayed no proteinuria up to 6
months of age. Renal function in MeRV mice was assessed
from urine protein-to-creatinine (P/C) ratios (Fig. 8). Lower
creatinine concentrations were observed in urine, contribut-
ing to elevated urine P/C ratios in the three MeRV transgenic
lines. This indication of renal dysfunction in 2- to 4-month-
old females was surprisingly consistent for all Vpr-positive
transgenic lines. The exception was T26 mice. Moribund
T26 mice had P/C ratios near 100, whereas surviving females
had a mean P/C of 20 (n = 12).
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Vpr-related renal disease
The primary histopathological lesion observed in young
TV2 hemizygous animals was solidification of glomerular
tufts in a focal and segmental distribution (Fig. 9). In
nursing TV2 mice, disease was marked by glomerular
epithelial cell hyperplasia, adhesions to Bowman’s capsule,
diffuse glomerulosclerosis, marked thickening of Bowman’s
capsule, and periglomerular fibrosis (TV2*, Fig. 9). The
tubular compartment contained atrophied cells and cells
containing protein reabsorption droplets. Tubules were di-
lated and, in some cases, proteinaceous casts were present.
The interstitium contained the occasional perivascular
mononuclear infiltrate. Neither hemizygous V13 (DVpr)
kidneys nor VN15 (DVprDNef) kidneys displayed these or
other signs of renal disease (not shown). The kidneys of 1-
month-old V13/TV2 double-transgenic mice displayed
widespread microcystic dilatation and FGS (Fig. 9) quite
distinct from the subtle changes observed in TV2 mice of
the same age. The histopathological condition of VN15/
TV2 kidneys was indistinguishable from TV2 kidneys of
age-matched siblings (not shown).
Consistent in the histopathological analyses of MeRV
kidneys was the appearance of focal glomerulosclerosis
(FGS) in both lactating and nonlactating females (Fig. 9)
in the absence of tubular changes. All three MeRV lines
displayed FGS with evidence of epithelial cell proliferation,
reduced urinary space, and adhesions between glomerular
tufts and Bowman’s capsule. The most severely affected
animals were lactating females (MeRV21*, Fig. 9) where
P. Dickie et al. / Vir76Fig. 8. Urine protein/creatinine ratios for transgenic mice. Urine was
collected from groups of female mice (2–4 months old) and assayed for
protein and creatinine content on three successive days as a measure of
renal function. Mean ratios are plotted. The asterisk denotes groups of
animals significantly different ( P < 0.01) from nontransgenic controls
(FVB/N). Numbers of mice per group: FVB/N, 14; HIVDNef, 5; HIV/TV2,
8; MeRV4, 5; MeRV8, 5; MeRV21, 9; HIVDVpr, 8; HIVDVprDNef, 10.
Fig. 9. Kidney histopathology. Kidneys were fixed in 10% buffered
formalin, sectioned and stained with hematoxylin and eosin. A hemizygous
TV2 female and a nursing TV2* female are compared to a nontransgenic
female (FVB/N) to demonstrate varying degrees of histopathology.
Glomerular condensation (obscuring capillary lumen) is visible in both
TV2 mice but tubular anomalies (acid-staining protein casts and fibrotic
lesions) are present predominantly in the nursing mouse (TV2*). Dual
transgenic TV2/V13 mice displayed focal glomerulosclerosis (FGS) and
tubular atrophy more severe than TV2 mice. MeRV (c-fms/vpr) mice from
three independent lines (4, 8, and 21) displayed FGS absent signs of tubular
histopathology. Mice were 5 to 10 weeks old. Original magnification was
400. The magnification scale bar in top left panel is equivalent to 30 Am.glomeruli appeared hypocellular and solidification was
more global.Discussion
A genetic analysis of HIVd1443 proviral transgenic mice
was undertaken to explore the role of HIV-1 Vpr in the
development of HIV-associated nephropathy (HIVAN). Two
HIVd1443 transgenes were associated with the development
of HIVAN (wild-type T26 and DNef X5 lines). In contrast,
two DVpr transgenes (in V13 and VN15 mice) failed to
induce HIVAN. A novel line bearing functional tat and vpr
P. Dickie et al. / Virology 322 (2004) 69–81 77genes (HIV[Tat/Vpr] mice) developed focal glomeruloscle-
rosis (FGS) further implicating Vpr in HIV-1 provirus-
induced FGS development. When vpr alone was transcribed
from the murine c-fms promoter in transgenic mice, FGS
was the principal histopathological lesion associated with
the development of renal insufficiency. Both the HIV-1 LTR
and the murine c-fms promoter are transcriptionally active in
murine macrophages. Thus, in addition to demonstrating the
ability of Vpr to induce FGS, the common features of the
two model systems suggest that HIVAN modeled in trans-
genic mice is related to viral gene expression in macro-
phages, or macrophage-like cells.
The full extent of renal disease in wild-type HIVd1443
transgenic mice may require viral genes other than vpr. A
transgene containing only the vpr gene (c-fms linked) is
sufficient to induce the fundamental glomerulopathic lesion,
but there is reason to suspect that tat and nef gene products
contribute to HIVAN. Renal disease, both in terms of FGS
and tubular degeneration, was enhanced in dual transgenic
progeny of TV2 by HIVd1443[DVpr] crosses compared to
TV2 animals alone. In contrast, the complementation of
HIVd1443[DVprDNef] transgenic mice with vpr (by TV2
crosses) did not exacerbate disease beyond that character-
izing TV2 mice. These observations implicate HIV-1 Nef in
disease progression. Earlier Nef-complementation experi-
ments (Kajiyama et al., 2000), and the incidence of inter-
stitial inflammation in CD4/HIV transgenic models (Hanna
et al., 1998), are consistent with this interpretation. Tat may
have contributed directly to FGS in HIV[Tat/Vpr] mice
because these animals were more compromised than c-
fms/vpr transgenic animals. Alternatively, any Tat effect
could have been indirect. The expression of vpr was higher
in the kidneys of TV2 mice than in c-fms/vpr mice, perhaps
because Tat transactivation of the viral LTR can occur in
murine cells (Murphy et al., 1993). Likewise, posttranscrip-
tional phenomena may explain the reduced expression of
vpr in HIVd1443[DNef] mice (relative to wild-type T26
mice) suggestive of an indirect effect of Nef. Importantly,
the presence or absence of secondary HIV genes may have
influenced spicing patterns, altering viral transgene expres-
sion in HIV transgenic mice (Fig. 5) in ways unrelated to
transgene position effects. Whether viral gene products such
as Tat and Nef contribute directly to renal disease remains a
matter requiring clarification.
Pathologic changes in human HIVAN occur in the
glomerular epithelia, notably podocytes, and the central
lesion in HIVAN is focal glomerulosclerosis (FGS)
(D’Agati and Appel, 1998). A direct effect of HIV-1 on
glomerular podocyte proliferation has been proposed both
for HIV-1-infected human podocytes and podocytes in
HIVd1443 transgenic animals (Barisoni et al., 1999; Nelson
et al., 2002). The development of FGS in c-fms/vpr trans-
genic animals strongly suggests that glomerular macro-
phages play a role in HIVAN. In exon 2 c-fms/EGFP
transgenic mice, c-fms promoter activity was restricted to
macrophages in the renal epithelia (Sasmono et al., 2003).There is evidence however that human and murine mesan-
gial cells express c-fms (Mori et al., 1990; Watanabe et al.,
2001). If mesangial cell expression of c-fms is much less
than that in macrophages, it is possible that c-fms expression
in mesangia of c-fms/EGFP transgenic mice (Sasmono et al.,
2003) escaped detection. Anomalies have been attributed to
murine mesangial cells in HIVd1443 mice (Singhal et al.,
1998), thus mesangium remain a potential source and target
of toxic viral gene products in humans as well as our murine
models. Whatever the cell type expressing Vpr (glomerular
epithelia or macrophages), pathologic effects could be
exerted on proximal bystander cells. This could be due to
the action of extracellular Vpr (Azad, 2000) or alterations in
the local production of host cell factors (cytokines, growth
factors). It seems clear however that endogenous renal
expression of HIV-1 products is necessary for glomerulop-
athy to develop (Bruggeman et al., 1997).
Viral gene expression in kidneys of HIVd1443 trans-
genic mice was first observed just before weaning age
(Dickie et al., 1991). The factors inducing viral gene
expression at this time are unknown. Considering the
transient nature of proteinuria in HIVd1443 mice, and the
edema peculiar to nursing transgenic mice, it is reasonable
to invoke a role for host factors in disease development.
The enhanced morbidity in nursing mice may be related
not so much to increased Vpr expression, but to the
sensitivity of glucocorticoid responsive genes to modula-
tion by Vpr (Kino et al., 1999). One possibility is that Vpr
expressed in a critical subset of kidney cells induces renal
damage by augmenting glucocorticoid responsiveness. This
hypothesis is credible given the renal toxicity of dexameth-
asone (Chen et al., 1998) and the capacity of glucocorti-
coids to modulate the turnover of extracellular matrix by
glomerular mesangium (Eberhardt et al., 2002; Kuroda et
al., 2002). In view of its well-documented effects on cell-
cycle control (Trono, 1995), Vpr toxicity may prove to be
multifactorial.
The HIV LTR is responsive to glucocorticoid action and
inflammatory stimuli. Were Vpr to enhance glucocorticoid
action in the context of glomerular disease, an augmenting
effect on HIV gene expression might have been observed.
This interplay may explain, in part, why HIV-linked trans-
genes were associated with higher levels of vpr expression
than was the c-fms-linked transgene. The exon-2 c-fms
promoter contains no glucocorticoid response element
(Sasmono et al., 2003). The combined effects of Vpr
action and disease development could elevate HIV LTR-
linked expression to levels not attained by the c-fms/vpr
transgene.
In addition to clarifying the involvement of HIV-1 gene
products in HIVAN, HIV transgenic model systems should
be useful in understanding and targeting infected macro-
phages in counteracting HIV-1 persistence. It is important in
the application of sustaining antiretroviral therapy to under-
stand the concerted impact of viral gene products on
proviral activity and immune dysfunction in tissue macro-
P. Dickie et al. / Virology 322 (2004) 69–8178phages. Illuminating the unique characteristics of HIV-
positive macrophages should lead to the conception of novel
approaches to augment normal cellular immune responses
and, better, to effect the removal of persistently infected
cells from HIV-infected individuals.Table 2
PCR primers
Name Primer sequence (5V–3V) Position
PDN3 GGTGGGAGCAGTATCGAGACCT 8873–8896
PDN2 CCAGAGAGCTCCCAGGCTCAGATCTGG 9546–9572
LV1 GAGGACAGATGGAACAAGCC 5551–5570
RV1 CTAGGATCTACTGGCTCC 5832–5849
L2 GGACGTATAGTTAGTCCTAGGTGTGA 5416–5441
VH2 CTTACTGCTTTGATAGAGAAGCTT 6026–6049
045 CTGAGCCTGGGAGCTCTCTGGC 477–498
R3 TACAGCTGCCTTGTAAGTCAT 9021–9041
5FMS CCCAGGACTTGGCCATCTGTTTCT 6857–6880*
5GAPDH AATGCATCCTGCACCACCAA
3GAPDH GTAGCCATATTCATTGTCATA
The primers used for PCR genotyping of HIV-1 transgenic mice and for RT-
PCR analysis of tissue RNA are listed. HIV-specific sequences and base
positions were derived from the sequence of HIV-1 proviral DNA in
pEVd1443 (Felser et al., 1989). Asterisk (*) denotes base position of primer
in p7.2fms-EGFP.Materials and methods
Transgene construction and animals
To create DGag/Pol proviral HIV transgenic mouse lines
deficient in Vpr, or Vpr and Nef, frameshift mutations were
introduced into pEVd1443 HIV DNA (Felser et al., 1989)
and pEVd1443[DNef] DNA (Kajiyama et al., 2000) by
cleavage at an EcoRI restriction enzyme site in the vpr gene
(Fig. 1). DNA ends were blunt-ended with DNA polymer-
ase I and rejoined with DNA ligase. In preparation of
pTV2, the source of HIV[Tat/Vpr] transgene DNA, nef was
deleted from pEVd1443 by excising the sequence between
the unique BamHI site (position 8465) and KpnI at position
9005 and replacing it with the vpr open reading frame
between positions 5480 and 5895 (RsaI sites) by blunt-end
ligation. The sequence between NsiI and SspI sites of this
plasmid (base 1247 to base 6153) was removed and
replaced with a 395 bp (5348–5743) fragment produced
by PCR amplification of the vpr gene (digested with PstI
and EcoRI) and a 410 bp EcoRI/SspI fragment (5347–
6153) by three-fragment ligation. The end-product, plasmid
pTV2, contained a proviral derivative in which vpr genes
flanked tat in its native position. MeRV mice carried a c-
fms/vpr transgene derived from p7.2fms-EGFP (Sasmono et
al., 2003) in which the RsaI vpr fragment replaced EGFP.
For embryo microinjection, plasmid DNAs were digested
with FspI and NaeI (HIV), or PvuI (c-fms/vpr), and purified
from agarose. Microinjection of fertilized FVB/N  FVB/N
embryos followed standard procedures (Hogan et al.,
1986).
FVB/N mice were purchased from Taconic Farms Inc.
(Germantown, NY). Transgenic mouse lines were main-
tained in the hemizygous state through backcrosses with
FVB/N mice. Transgenic offspring were identified either by
the presence of HIV-induced perinatal cataracts (Dickie,
1996) or PCR analysis of mouse genomic DNA. They were
housed in a conventional breeding facility, fed standard
chow, and handled according to CCAC guidelines.
Northern blot analyses
Total RNA (40 Ag for kidney, 20 Ag for other tissues),
extracted using an acid-guanidinium procedure (Chomc-
zynski and Sacchi, 1987), was fractionated in 1.25%
denaturing (2.2 M formaldehyde) agarose and blotted onto
Nytran membranes (Schleicher and Schuell Inc., Keene,
NH). UV cross-linked membranes (Stratagene, La Jolla,
CA) were hybridized with a 32P-dCTP-labeled probederived from a Nef cDNA for the detection of HIV-
specific transcripts (Dickie et al., 1991). An RNA molec-
ular weight ladder was obtained from Life Technologies
(Bethesda, MD). Membranes were stripped and rehybri-
dized with a 32P-dCTP-labeled probe for human h-actin
(Clontech, Palo Alto, CA) to control for loading discrep-
ancies. The animals represented were between 24 and 35
days old.
Urine analyses
Spontaneously released urine samples were collected and
analyzed immediately for protein and creatinine content.
Protein (mg/dl) was determined using Bradford reagent
(Bio-Rad Lab., Hercules, CA). Urine creatinine levels were
measured using a commercially available kit (Sigma Corp.,
St. Louis, MO). Individual animals were tested on three
successive days and mean values computed.
Histochemistry and electron microscopy
For histochemical analysis, kidneys from 1- to 2-month-
old female mice were halved by a longitudinal midline cut
and fixed in 10% buffered formalin. Five-micrometer
sections were stained with hematoxylin and eosin. A
pathologist (RU) blinded to the animal genotype performed
the histological evaluation of c-fms/vpr transgenic tissue.
Frozen sections (4 Am) of kidneys (in OCT) were immu-
nostained with rabbit polyclonal antiserum raised against a
peptide of Vpr (residues 1–46; AIDS Reagent and Refer-
ence Depository, Rockville, MD). After washing, the
sections were incubated with Alex-488 conjugated goat
anti-rabbit IgG (Molecular Probes, Oregon). For electron
microscopy, renal tissue from 25-week-old mice was fixed
in 2.5% glutaraldehyde in 0.1 M cacodylate buffer and
embedded in glycolmethacrylate. Thin sections were
stained with osmium tetroxide and examined by transmis-
sion electron microscopy.
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Transgenes were routinely detected in mouse genomic
DNA by PCR using the primer pairs listed in Table 2. For
the detection of HIVd1443 sequences: PDN3/PDN2; for
TV2 sequences: LV1/PDN2; and for c-fms/vpr sequences:
5FMS/RV1. For RT-PCR detection of native vpr transcripts,
the primer pair L2/VH2 was used with HIV transgenic
lysates and LV1/RV1 was used for c-fms/vpr transgenic
lysates. Alternative spliced products in HIVd1443 lysates
were analyzed using the 045/RV1 primer pair. The 3V vpr
gene transcript of the TV2 transgene was detected with LV1/
R3. GAPDH primers are also listed in Table 2. Semiquan-
titative RT-PCR was performed on total RNA or mRNA
partially purified by a single selection on oligo-dT cellulose.
RNA (2 Ag total or 0.5 Ag mRNA) was reverse transcribed
with Superscript II (Life Technologies). Undiluted, two- and
tenfold serial dilutions of cDNA were subjected to PCR
amplification in triplicate. PCR cycles were determined
empirically to yield linear results. Standard amplification
conditions were 94 jC for 2 min, 60 jC for 1 min, 75 jC for
1.5 min, 94 jC for 30 s. For the labeling of PCR products,
32P-dCTP (0.13 AM) replaced cold dCTP in the reaction
mix. Unlabeled products were visualized in 1% agarose gels
stained with ethidium bromide. Labeled products were
fractionated in 5% acrylamide and exposed to X-ray film.
The DNA ladder was obtained from Life Technologies.
Computational analyses
Individual values were computed as the average of
triplicate experiments. Group means were subjected to
statistical analyses (t test) using SigmaPlot8.0 graphics
software (SSPS Science). Error bars denote single standard
deviations.
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